Qin, S;
Finn, RS;
Kudo, M;
Meyer, T;
Vogel, A;
Ducreux, M;
Macarulla, TM;
... Zhu, AX; + view all
(2019)
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Future Oncology
, 15
(16)
pp. 1811-1822.
10.2217/fon-2019-0097.
Preview |
Text
Meyer_RATIONALE 301 stud. Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma_VoR.pdf - Published Version Download (7MB) | Preview |
Abstract
Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Tislelizumab, an investigational, humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, has demonstrated preliminary antitumor activity in HCC. Here we describe a head-to-head Phase III study comparing the efficacy, safety and tolerability of tislelizumab with sorafenib as first-line treatment in unresectable HCC.
| Type: | Article |
|---|---|
| Title: | RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/fon-2019-0097 |
| Publisher version: | https://doi.org/10.2217/fon-2019-0097 |
| Language: | English |
| Additional information: | © 2019 Future Science Group. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | HCC, PD-1, hepatocellular carcinoma, tislelizumab |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10077677 |
Archive Staff Only
 |
View Item |
